Investor Expectations to Drive Momentum within Criteo S.A, Prima BioMed, CoStar Group, DBV Technologies S.A, Hollysys Automation Technologies, and China Biologic Products — Discovering Underlying Factors of Influence

NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) — In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Criteo S.A. (NASDAQ:), Immutep Limited (NASDAQ:), CoStar Group, Inc. (NASDAQ:), DBV Technologies S.A. (NASDAQ:), Hollysys Automation Technologies, Ltd. (NASDAQ:), and China Biologic Products Holdings, Inc. (NASDAQ:), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

CRTO DOWNLOAD:
IMMP DOWNLOAD:

CSGP DOWNLOAD:

DBVT DOWNLOAD:

HOLI DOWNLOAD:

CBPO DOWNLOAD:

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Criteo S.A. (NASDAQ:), Immutep Limited (NASDAQ:), CoStar Group, Inc. (NASDAQ:), DBV Technologies S.A. (NASDAQ:), Hollysys Automation Technologies, Ltd. (NASDAQ:), and China Biologic Products Holdings, Inc. (NASDAQ:) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today‘s readers below.

—————————————–

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed April 11th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

—————————————–

CRITEO S.A. (CRTO) REPORT OVERVIEW

Criteo S.A‘s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Criteo S.A reported revenue of $674.03MM vs $566.83MM (up 18.91%) and basic earnings per share $0.82 vs $0.63 (up 30.16%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Criteo S.A reported revenue of $2,296.69MM vs $1,799.15MM (up 27.65%) and basic earnings per share $1.40 vs $1.30 (up 7.69%). Criteo S.A is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.28. The estimated EPS forecast for the next fiscal year is $1.78 and is expected to report on February 13th, 2019.

To read the full Criteo S.A. (CRTO) report, download it here:

—————————————–

IMMUTEP LIMITED (IMMP) REPORT OVERVIEW

Prima BioMed‘s Recent Financial Performance

For the twelve months ended June 30th, 2017 vs June 30th, 2016, Prima BioMed reported revenue of $3.18MM vs $1.48MM (up 115.29%) and basic earnings per share -$0.30 vs -$2.02.

To read the full Immutep Limited (IMMP) report, download it here:

—————————————–

COSTAR GROUP, INC. (CSGP) REPORT OVERVIEW

CoStar Group‘s Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, CoStar Group reported revenue of $253.99MM vs $218.31MM (up 16.34%) and basic earnings per share $1.28 vs $0.92 (up 39.13%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, CoStar Group reported revenue of $965.23MM vs $837.63MM (up 15.23%) and basic earnings per share $3.70 vs $2.64 (up 40.15%). CoStar Group is expected to report earnings on April 23rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.88. The estimated EPS forecast for the next fiscal year is $8.43 and is expected to report on February 20th, 2019.

To read the full CoStar Group, Inc. (CSGP) report, download it here:

—————————————–

DBV TECHNOLOGIES S.A. (DBVT) REPORT OVERVIEW

DBV Technologies S.A‘s Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, DBV Technologies S.A reported revenue of $13.46MM vs $10.05MM (up 33.91%) and basic earnings per share -$3.38 vs -$2.59.

To read the full DBV Technologies S.A. (DBVT) report, download it here:

—————————————–

HOLLYSYS AUTOMATION TECHNOLOGIES, LTD. (HOLI) REPORT OVERVIEW

Hollysys Automation Technologies‘ Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Hollysys Automation Technologies reported revenue of $157.40MM vs $99.14MM (up 58.77%) and basic earnings per share $0.60 vs $0.17 (up 252.94%). For the twelve months ended June 30th, 2017 vs June 30th, 2016, Hollysys Automation Technologies reported revenue of $431.94MM vs $544.33MM (down 20.65%) and basic earnings per share $1.15 vs $2.00 (down 42.50%). Hollysys Automation Technologies is expected to report earnings on May 10th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.22.

To read the full Hollysys Automation Technologies, Ltd. (HOLI) report, download it here:

—————————————–

CHINA BIOLOGIC PRODUCTS HOLDINGS, INC. (CBPO) REPORT OVERVIEW

China Biologic Products‘ Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, China Biologic Products reported revenue of $90.11MM vs $77.63MM (up 16.08%) and basic earnings per share -$0.88 vs $0.69. For the twelve months ended December 31st, 2017 vs December 31st, 2016, China Biologic Products reported revenue of $370.41MM vs $341.17MM (up 8.57%) and basic earnings per share $2.40 vs $3.79 (down 36.68%). China Biologic Products is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $1.32. The estimated EPS forecast for the next fiscal year is $5.84 and is expected to report on February 27th, 2019.

To read the full China Biologic Products Holdings, Inc. (CBPO) report, download it here:

—————————————–

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world‘s leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets‘ roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets‘ oversight and audit staff are registered analysts, brokers, and/or financial advisers (“Registered Members”) working within Equity Research, Media, and Compliance departments. Fundamental Markets‘ roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets‘ Compliance department by Phone, at +, or by E-mail at compliance-Markets.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media :
Andrew Duffie, Media Department
Office: +
media-Markets

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please a partner network manager at partnership-Markets.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.